Role of L-Methylfolate in Treatment of Depression

Director Principal Government medical college and hospital Chandigarh0 个研究点目标入组 67 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Patients with primary diagnosis of moderate to severe depression according to ICD-10 DCR criteria. These patients should be treatment naÃ¯ve or if receiving treatment should have regular compliance to it for at least 6 weeks and not be responding to the current treatment as defined by response of <50% of global improvement as reported by the patient and the caregivers.
•2) Patients having HAM-D score of >=17, at time of intake which indicates at least moderate degree of depression.
•3) Patient and his/her relative willing to give informed consent.

•1) Breastfeeding, and pregnant females
•2) Having a current serious suicide risk, or psychotic symptoms
•3) Unstable medical illness requiring concomitant use of other medication including those medications which are known to have depressogenic effect ( corticosteroids, anti-epileptics, beta-blockers, quinolone class of antibiotics, interferons, anti-neoplastic drugs).
•4) Having an active substance use disorder within the past 6 months (in terms of fulfilling criteria for substance-harmful use or substance dependence) except nicotine and caffeine use.
•5)Having past history of mania/hypomania (including antidepressant-induced), psychotic symptoms, or seizure disorder.
•6)Taking vitamins or dietary supplements containing folate or vitamin B12.
•7)Having comorbid diagnosis of intellectual disability, dementia, Alzheimerâ??s disease, or Parkinsonâ??s disease.

发起方

Director Principal Government medical college and hospital Chandigarh